- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets | 144 | GlobeNewswire (Europe) | NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy company with global manufacturing and IP control.Approximately... ► Artikel lesen | |
| Di | NKGen Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.08. | NKGen Biotech, Inc.: NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit | 1 | GlobeNewswire (USA) | ||
| 21.07. | NKGen Secures FDA Expanded Access For NK Cell Therapy In Neurodegenerative Diseases, Stock Down | 3 | RTTNews | ||
| 21.07. | FDA genehmigt erweitertes Zugangsprogramm für NKGen-Zelltherapie bei neurodegenerativen Erkrankungen | 2 | Investing.com Deutsch | ||
| 21.07. | FDA grants expanded access for NKGen's cell therapy in neurodegenerative diseases | 1 | Investing.com | ||
| NKGEN BIOTECH Aktie jetzt für 0€ handeln | |||||
| 17.07. | NSE - NKGen Biotech, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 3 | SEC Filings | ||
| 16.07. | NKGen Biotech announces new funding to regain compliance with reporting obligations and listing standards | 1 | Seeking Alpha | ||
| 16.07. | NKGen Biotech, Inc.: NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards | 114 | GlobeNewswire (Europe) | Funding in the amount of $2.0M from Japanese strategic investor, in the form of common equity PIPE with warrants. New funding provides for necessary resources to regain compliance with reporting... ► Artikel lesen | |
| 16.07. | NKGen Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.07. | NKGen administers first dose of NK cell therapy to Alzheimer's patient | 1 | Investing.com | ||
| 10.07. | NKGen verabreicht Alzheimer-Patienten erste Dosis einer neuartigen NK-Zelltherapie | 1 | Investing.com Deutsch | ||
| 10.07. | NKGen Biotech, Inc.: NKGen Biotech Administers First Dose of Troculeucel to Alzheimer's Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy | 116 | GlobeNewswire (Europe) | SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization... ► Artikel lesen | |
| 23.06. | NKGen Biotech, Inc.: NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer's Trial with Activation of Clinical Sites in Canada and Florida | 144 | GlobeNewswire (Europe) | SANTA ANA, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization... ► Artikel lesen | |
| 20.06. | NKGen Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | NKGen Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | NKGen CEO puts skin in the game, investing $2.6M to move biotech toward Alzheimer's readout | 8 | FierceBiotech | ||
| 08.05. | NKGen Biotech, Inc.: NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations | 121 | GlobeNewswire (Europe) | New funding from Dr. Song augments $3.0 million in funding advances from AlpineBrook Capital in 2025 above and beyond the $5.5 million proceeds and additional $4 million commitments in previously-disclosed... ► Artikel lesen | |
| 08.05. | NKGen Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.05. | NKGen Biotech, Inc.: NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
| BIOXXMED | 0,300 | 0,00 % | PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025 | DJ PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
bioXXmed AG: Ergebnis für... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| OCUGEN | 0,893 | +2,48 % | Ocugen, Inc. - 8-K, Current Report | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| BIO-GATE | 0,900 | 0,00 % | EQS-DD: Bio-Gate AG: Karl Richter, Zeichnung von Wandelschuldverschreibungen | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
21.08.2025 / 17:58... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,472 | +11,58 % | Defence Therapeutics Inc.: Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth | Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in... ► Artikel lesen | |
| VAXART | 0,280 | 0,00 % | Vaxart, Inc. - 8-K, Current Report | ||
| BURCON NUTRASCIENCE | 1,400 | -3,45 % | Burcon NutraScience Corporation: Burcon Achieves First Commercial Production of Puratein(R)C Canola Protein | Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 5,290 | +5,38 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit | ||
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland | Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Ampligen... ► Artikel lesen | |
| IMMUNIC | 0,723 | +4,03 % | EQS-News: Immunic AG: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Patent
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| CEL-SCI | 10,605 | 0,00 % | Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): BUY | Original-Research: CEL-SCI Corporation - from First Berlin Equity Research GmbH
01.09.2025 / 13:38 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen |
NKGEN BIOTECH INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,190 Euro und damit -0,52 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NKGEN BIOTECH INC finden Sie auf Wallstreet Online.